CymaBay Therapeutics

CymaBay Therapeutics

Verified
Developing therapies for liver and other chronic diseases with high unmet medical need

Launch date
Employees
Ownership
Market cap
$331m
Net debt
$63.9m
Firm valuation
$233m (Public information from Aug 2022)
Hayward California (HQ)

Financials

Edit
Revenues, earnings & profits over time
USD2016201720182019202020212022E
Revenues-10m--6m8m6m
% growth-----33 %(25 %)
EBITDA-(21m)(72m)(60m)(62m)--
% EBITDA margin-(210 %)--(1033 %)--
Profit-27m(72m)(89m)(111m)(77m)(90m)
% profit margin-270 %--(1850 %)(963 %)(1500 %)
EV / revenue-40.4x---36.4x54.5x
EV / EBITDA--18954.0x-----
R&D budget--56.1m82.5m---

Source: Company fillings or news article

  • Edit
DateInvestorsAmountRound
-N/A-
Not yet verified
N/A$10mEarly VC
N/A$27mLate VC
N/AN/A-
Not yet verified
$44mSeries B
N/A$10mSeries C
Not yet verified
$32mSeries D
$27.7mDebt
N/A$8.6mEarly VC
$5mDebt
N/AN/AIPO
$325kPost IPO Debt
$100mPost IPO Debt
Total Funding$122m

Recent News about CymaBay Therapeutics

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.